Gilead Sciences (GILD) Tops Q4 EPS by 19c, Offers Guidance
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
EPS Growth %: -462.7%
Financial Fact:
Product sales: 7.41B
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.90, $0.19 better than the analyst estimate of $1.71. Revenue for the quarter came in at $7.6 billion versus the consensus estimate of $7.16 billion.
GUIDANCE:
Gilead Sciences sees FY2025 EPS of $7.70-$8.10, versus the consensus of $7.54. Gilead Sciences sees FY2025 revenue of $28.2-28.6 billion, versus the consensus of $28 billion.
For the full-year 2025, Gilead expects:
(in millions, except per share amounts) |
| February 11, 2025 Guidance | |||||
| Low End |
| High End | ||||
Product sales |
| $ | 28,200 |
| $ | 28,600 | |
Product sales excluding Veklury |
| $ | 26,800 |
| $ | 27,200 | |
Veklury |
| $ | 1,400 |
| $ | 1,400 | |
Diluted EPS |
| $ | 5.95 |
| $ | 6.35 | |
Non-GAAP diluted EPS |
| $ | 7.70 |
| $ | 8.10 | |
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Rubio to visit Gulf states amid Iran deal concerns
- Alphabet (GOOGL) call put ratio 1.6 calls to 1 put with a focus on June 22 weekly calls as share price down 6%
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
